Romidepsin is the only FDA-approved peptide drug designed specifically to target epigenetic mechanisms, with approvals for cutaneous and peripheral T-cell lymphoma in 2009 and 2011. Nesiritide, approved in 2001 as a heart-failure vasodilator, has been repurposed on epigenetic grounds, though the…
Two FDA-approved, peptide-derived drugs carry this topic's weight. Romidepsin, a bicyclic depsipeptide, was the first peptide-derived epigenetic drug to reach approval, according to a vendor analysis, and it is the only FDA-approved peptide medicine designed specifically to target epigenetic effects. Its two approvals cover T-cell lymphomas. Nesiritide, a recombinant human B-type natriuretic peptide, was approved in 2001 as a vasodilator for acute decompensated heart failure and has since been claimed to act through epigenetic mechanisms as well. The same source reports that neither drug is approved by the European Medicines Agency EMA in the European Union.
The reader question asks which peptide-derived drugs target epigenetic mechanisms and what their approved indications and regulatory status are. The answer has two layers. The first is the regulatory record, which is concrete: romidepsin was approved by the FDA in 2009 for cutaneous T-cell lymphoma CTCL and in 2011 for peripheral T-cell lymphoma PTCL ; nesiritide was approved in 2001 for symptomatic treatment of acute decompensated heart failure. The second layer is mechanistic, and it is thinner. The supplier material that ties the two drugs together describes romidepsin as a methylation inhibitor and says nesiritide has been repurposed because of its epigenetic effects, but it supplies no experimental detail for either claim.
A 2019 peer-reviewed survey puts the clinical picture in perspective: peptides from endogenous, dietary, environmental, and synthetic sources can modulate epigenetic processes including DNA methylation and histone acetylation, yet only two FDA-approved peptide drugs have a proven epigenetic mechanism of action PMID 31300053 . That count of two sits alongside the vendor's count of one drug designed for epigenetic targeting. The two statements do not conflict: "designed specifically for epigenetic effects" and "proven to act through an epigenetic mechanism" are different standards, and the sources are not describing the same drug set. This article works through both records, separates what is documented from what is asserted, and points to what a researcher or buyer should verify before acting on either drug's story.
Romidepsin is a bicyclic depsipeptide, a natural-product-derived molecule in which a peptide backbone is closed into a ring with an ester linkage. Its established pharmacology is inhibition of histone deacetylases HDACs , specifically the class I enzymes. HDACs remove acetyl groups from lysine residues on histone tails. When they are inhibited, acetylation accumulates, chromatin adopts a more open conformation, and the expression of genes controlling proliferation, differentiation, and apoptosis shifts. That is the mechanism generally invoked to explain the drug's activity in T-cell lymphomas: the prevailing model is that HDAC inhibition changes the acetylation balance and drives malignant T cells into cell-cycle arrest and apoptosis.
The two approved diseases are distinct within the T-cell lymphoma family. CTCL covers skin-homing T-cell lymphomas, a group that includes mycosis fungoides and Sézary syndrome, in which malignant T lymphocytes accumulate in the skin. PTCL is a heterogeneous set of mature T-cell lymphomas arising outside the skin, generally rarer and more aggressive. Both are areas of substantial unmet need, which is part of why a molecule aimed at an epigenetic regulator drew oncologic attention. The drug is given by intravenous infusion, and its two FDA approvals, in 2009 for CTCL and 2011 for PTCL, are the clinical facts on which its use rests.
This matters because the vendor material that profiles romidepsin labels it a "methylation inhibitor." Methylation and acetylation are both epigenetic modifications, but they are biochemically distinct. DNA methylation is the addition of methyl groups to cytosine residues, catalyzed by DNA methyltransferases. Histone acetylation is the addition and removal of acetyl groups on histone proteins, catalyzed by acetyltransferases and deacetylases. A drug can affect one without affecting the other. The 2019 review in Clinical Epigenetics treats both modifications as targets of peptide-based modulators PMID 31300053 , which may explain the loose grouping, but the conflation is not harmless: a researcher planning an experiment around presumed DNA methylation effects would design it differently from one studying histone acetylation. The source provides no evidence that romidepsin inhibits DNA methylation, and the drug's documented mechanism points to HDAC inhibition instead.
The distinction also bears on the drug's clinical record. Romidepsin's FDA approvals rest on demonstrated efficacy in CTCL in 2009 and PTCL in 2011, not on a published account of its epigenetic mechanism. The mechanism is plausible, and the drug is a bona fide epigenetic agent in the broad sense, since HDAC activity is an epigenetic regulatory process. But the chain from molecular target to clinical response in these lymphomas remains an active research question rather than a settled fact. The vendor's assertion that methylation inhibition explains the anti-lymphoma effect is not supported by any citation in the source, and no such mechanism appears in the evidence assembled here.
The approval timeline for the two drugs is the firmest ground in this topic, and it is short: two FDA approvals for romidepsin, one for nesiritide, and no EMA approvals for either. The table below sets out that record.
| Drug | Compound class | FDA approval | Approved indication at approval | Principal mechanism | EMA status |
| --- | --- | --- | --- | --- | --- |
| Romidepsin | Bicyclic depsipeptide | 2009, 2011 | CTCL 2009 ; PTCL 2011 | Class I HDAC inhibition | Not approved |
| Nesiritide | Recombinant human B-type natriuretic peptide | 2001 | Symptomatic acute decompensated heart failure | Vasodilation | Not approved |
Romidepsin's two approvals came in 2009 for cutaneous T-cell lymphoma and in 2011 for peripheral T-cell lymphoma. These are the indications a clinician or buyer should attach to the drug. Nothing in the approved record extends romidepsin to other cancers, lung fibrosis, or Epstein-Barr virus infections, the additional uses named in the vendor profile.
Nesiritide's 2001 approval for symptomatic treatment of acute decompensated heart failure rests on its vasodilating activity. The drug is recombinant human B-type natriuretic peptide; it binds natriuretic peptide receptors, raises intracellular cyclic GMP, and relaxes vascular smooth muscle, reducing the workload on a failing heart. That cardiovascular indication is what the FDA approved, and it remains the drug's approved use in the record examined here.
The regulatory gap is the second firm fact. According to the source, neither romidepsin nor nesiritide is approved by the EMA in the European Union. The practical consequence is that European clinicians and researchers do not have a standard EMA-authorized route to either drug; access depends on national provisions for unapproved medicines or on clinical trial participation. US approval does not confer European availability.
Nesiritide's original story is cardiovascular, not oncologic. B-type natriuretic peptide is a cardiac hormone secreted by the ventricular myocardium in response to wall stretch; in decompensated heart failure, endogenous levels rise but are insufficient to counter the hemodynamic stress. Nesiritide, the recombinant form, was developed to supplement that response. It was approved in 2001 for symptomatic treatment of acute decompensated heart failure, a condition in which the heart cannot maintain adequate output and fluid accumulates. The drug's vasodilating action, mediated through the natriuretic peptide receptor system, reduces both preload and afterload.
The source then reports that nesiritide has been repurposed because of its epigenetic effects. This is the weakest claim in the profile. The source names no disease targeted by the repurposing, no epigenetic enzyme or modification involved, no development stage, no trial registration, and no published result. The claim cannot be checked, and it should not be repeated as fact. A reader who wants to evaluate it would need at minimum a named target, a registered trial identifier, or a peer-reviewed publication. None of those appear in the vendor material, and none appears in the evidence assembled for this article.
One plausible reading is worth stating, with its limits. The 2019 review reports that exactly two FDA-approved peptide drugs have a proven epigenetic mechanism of action and identifies them as romidepsin and nesiritide PMID 31300053 . The vendor counts one drug designed for epigenetic targeting, romidepsin. If the review's count of two is accurate, the second drug could be nesiritide, which would make the vendor's repurposing narrative coherent. But the supplied evidence does not identify the second drug, and no mechanism has been demonstrated here. The identification is a hypothesis, not a finding.
Separating documentation from assertion is the core task of this topic, so the evidentiary record deserves its own accounting. On the regulatory side, the record is solid. Romidepsin's approvals for CTCL and PTCL, in 2009 and 2011, are public FDA actions, and nesiritide's 2001 approval for acute decompensated heart failure is public FDA action as well. These are the facts a buyer or clinician can rely on. So is the source's statement that neither drug is EMA-approved in the European Union.
The peer-reviewed literature supplies the mechanistic context. A 2019 review in Clinical Epigenetics concludes that peptides from endogenous, dietary, environmental, and synthetic sources can modulate epigenetic processes such as DNA methylation and histone acetylation, but that only two FDA-approved peptide drugs have a proven epigenetic mechanism of action PMID 31300053 . That review does three things for this topic. It confirms that peptide-based epigenetic modulation is a real and active research area, with a scope far broader than two marketed drugs. It provides the count of two that coexists with the vendor's count of one. And it names the two relevant modifications, which is exactly where romidepsin's classification problem sits.
Reading the two counts together clarifies what each actually claims. The vendor's one answers a narrow question: how many approved peptide drugs were conceived and marketed as epigenetic agents. The review's two answers a broader one: how many have been shown to act through an epigenetic mechanism. A drug approved for one purpose and later found to act through a second mechanism could appear in the broader count without appearing in the narrower one. That is precisely the shape of the nesiritide story as the vendor tells it, which is why the two claims can both be true without either confirming the other.
A separate 2021 review covers brain-penetrating peptides and peptide-drug conjugates that exploit receptor-mediated transcytosis to deliver drugs across the blood-brain barrier for central nervous system diseases PMID 33470550 . That work is not about epigenetic mechanisms directly. It matters here because it shows the wider developmental arc of peptide therapeutics: peptides are being developed both as direct bioactive agents and as delivery vehicles for other drugs. When the source implies that peptide-derived epigenetic drugs are a growth area, the literature supports the general claim that peptides are versatile therapeutic scaffolds, while offering no support for the specific claims about nesiritide.
What the evidence does not establish is equally important. Nothing in the supplied record shows that romidepsin inhibits DNA methylation. Nothing identifies nesiritide's epigenetic target or the disease of its alleged repurposing. Nothing documents the additional uses attributed to romidepsin, which the source lists as other cancers, lung fibrosis, and Epstein-Barr virus infections. These are claims in a promotional brief, presented without trial identifiers, without citations, and without mechanistic reasoning.
For a researcher or buyer navigating this topic, the following distinctions matter. First, treat the FDA approvals as fact and everything else as claim. If a decision hinges on romidepsin's approved uses, those uses are CTCL and PTCL. If it hinges on a second, epigenetic use for nesiritide, no approved use of that kind exists in the record, and no regulatory status supports it.
Second, verify mechanism language before designing experiments. The word "epigenetic" covers DNA methylation, histone acetylation, and other modifications that are regulated by different enzyme systems. A vendor description of romidepsin as a methylation inhibitor does not match the drug's documented pharmacology as a class I HDAC inhibitor. An experiment built on the wrong mechanism will generate results that are hard to interpret and harder to publish. Check the primary literature for the specific enzyme and modification at issue.
Third, plan for regulatory geography. Both drugs are FDA-approved in the United States, and neither is EMA-approved in the European Union. A European buyer or investigator should confirm the applicable national route for unapproved medicines before assuming a product can be obtained, and should be aware that US approval does not confer European availability. A US buyer, by contrast, confronts fewer access questions for the approved indications, but should still verify that the intended research use is covered by the approved label.
Fourth, make suppliers and collaborators document their claims. When a purchase decision or a study design depends on a mechanism statement, request the primary citation. If a supplier cannot produce a trial identifier or a peer-reviewed reference for a stated indication, treat the indication as unverified. The romidepsin methylation label and the nesiritide repurposing both fail that test in the material examined here.
Fifth, use the literature to gauge the broader field rather than the marketing narrative. Researchers working on peptide-based epigenetic modulation can draw on evidence that peptides from diverse sources, including endogenous and dietary peptides, alter DNA methylation and histone acetylation PMID 31300053 . Those working on delivery can look at peptide-drug conjugates engineered for receptor-mediated transcytosis across the blood-brain barrier PMID 33470550 . The two reviews describe active research programs, and neither depends on the promotional claims reviewed here.
Three questions dominate the parts of this topic that remain open. The first is nesiritide's alleged repurposing: which disease is it being developed for, which epigenetic target does it engage, and at what stage of development is it? The source gives none of these details, and the peer-reviewed material cited here is silent on the drug. Until a named target or a trial identifier appears, the claim should be treated as unverified marketing narrative.
The second is the mechanism gap for romidepsin. The vendor's framing asks how methylation inhibition translates into anti-lymphoma activity, but that question presupposes a mechanism that is not established. The better question is how class I HDAC inhibition alters gene expression programs in malignant T cells to produce the clinical responses seen in the CTCL and PTCL trials. That question is answerable, but it requires experimental work, not a marketing brief.
The third is the size of the field. The vendor's count is 1; the review's count is 2 PMID 31300053 . The identity of the second drug is not established in the material examined here, and the development pipeline of peptide-derived epigenetic drugs is not documented in either source. The review's account of peptide modulators from dietary, endogenous, and synthetic sources suggests the research base is broader than the approved drug list, but breadth of published mechanism is not the same as a regulatory pathway. For anyone tracking this space, the honest summary is that the approvals are clear, the mechanisms are only partially documented, and the promotional claims outrun the evidence.
Peptides referenced: Nesiritide, B-type Natriuretic Peptide.
Related reading: Peptide Vaccine Development and Production Challenges, WorkBeads 40 IEX Resin Properties: Pore Size, Stability and Capacity, Five Reasons Crude Peptides Are Not Enough for Screening, Cation-Exchange Purification of Lactoferrin from Low-Fat Bovine Milk.